Cannabinoid medicine is at the cross-roads. Having come a long way from its roots in cultivation, cannabinoid drug development has entered the world of pharmaceutical R&D and drug development. Making this transition comes with its unique challenges and opportunities. As the scientific evidence is building up, the questions of due diligence in drug development, clearing the pathway for regulatory approvals, and de-risking investment are now front and center.

Join our expert panel discussion on the considerations that underpin the development of cannabinoid-based pharmaceuticals. Our panel of esteemed experts will explore opportunities, challenges, and ways (for big pharma and emerging biotech alike) to de-risk investment in cannabinoid medicines development, from formulation and delivery, to regulatory hurdles and clinical trials, with a focus on differentiating innovation.

Don't miss this opportunity to be part of a dynamic conversation that is shaping the future of evidence-based medicine.